Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | President | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,504 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Gift · Disposed 123,407 · Balance 130,504 F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy spousal trust | 123,407 |
Reported balance
Holding disclosure · report date 2026-09-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 123,407 F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 40,297 | $0.67 | $26,998.99 |
DisclosureSEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 3 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 4,326 | $4.22 | $18,255.72 |
DisclosureSEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 9,106 | $0.67 | $6,101.02 |
DisclosureSEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-23-000237 · doc4.xml · derivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,202 Underlying: Common Stock · 4,500 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter. F2 · balance_after: On April 2, 2021, the reporting person filed a Form 4 which inadvertently reported in column 9 that, following his exercise of an option, the number of derivative securities beneficially owned was 265,414 shares, when this number should have been reported as 253,414 shares. This Form 4 reflects the corrected number of derivative securities beneficially owned following the transactions reported since April 2, 2021, including the transaction reported herein. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 4,500 | $0.67 | $3,015.00 |
DisclosureSEC source: 0000899243-23-000237 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 02:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,652 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0000899243-22-038538 · doc4.xml · derivative · entry 7 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,326 Underlying: Common Stock · 8,652 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: The option award vests upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 02:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,211 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-22-038538 · doc4.xml · derivative · entry 6 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,491 Underlying: Common Stock · 18,211 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: 25% of the shares subject to the stock option vested on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 02:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,383 | $43.87 | $236,152.21 |
DisclosureSEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 5 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,462 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $44.06, inclusive. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.76 to $44.06, inclusive. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 02:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 13,933 | $43.15 | $601,208.95 |
DisclosureSEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 4 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,845 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $44.06, inclusive. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.76 to $43.75, inclusive. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 02:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 31,699 | $42.30 | $1,340,867.70 |
DisclosureSEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 3 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,778 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $44.06, inclusive. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $42.71, inclusive. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 02:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 8,652 | $4.22 | $36,511.44 |
DisclosureSEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 02:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 18,211 | $0.67 | $12,201.37 |
DisclosureSEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 12, 2022 Filed Dec 20, 2022 21:05 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,211 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-22-039103 · doc4a.xml · derivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,106 Underlying: Common Stock · 18,211 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On December 14, 2022, the reporting person filed a Form 4 which inadvertently attributed a stock option exercise to the incorrect stock option award. The stock option that was the subject of the reported exercise is the stock option award originally reported on September 9, 2021. Accordingly, the first line of Table 2 of this Form 4 reflects this correction. F2 · kind: The stock option exercise was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The option award vests upon the achievement of a closing price hurdle following Beam Therapeutics Inc.'s initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Read SEC document |
| March 31, 2022 Filed Apr 5, 2022 00:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,859 | $59.11 | $109,885.49 |
DisclosureSEC source: 0000899243-22-013489 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,614 F2 · shares: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs. Read SEC document |
| March 31, 2022 Filed Apr 5, 2022 00:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013489 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,473 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $69.21 | $0.00 |
DisclosureSEC source: 0000899243-22-004198 · doc4.xml · derivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: The option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the reporting person's continued service with Beam Therapeutics Inc. through each vesting date. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,700 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-21-050117 · doc4.xml · derivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,702 Underlying: Common Stock · 39,700 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with Beam Therapeutics Inc. through such dates. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 39,700 | $0.67 | $26,599.00 |
DisclosureSEC source: 0000899243-21-050117 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,607 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0000899243-21-049634 · doc4.xml · derivative · entry 5 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,646 Underlying: Common Stock · 2,607 shares Expires 2029-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 290 | $87.34 | $25,328.60 |
DisclosureSEC source: 0000899243-21-049634 · doc4.xml · nonDerivative · entry 4 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,773 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,101 | $86.62 | $95,368.62 |
DisclosureSEC source: 0000899243-21-049634 · doc4.xml · nonDerivative · entry 3 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,063 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.15 to $86.99, inclusive. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,216 | $85.39 | $103,834.24 |
DisclosureSEC source: 0000899243-21-049634 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,164 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.88, inclusive. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 2,607 | $7.22 | $18,822.54 |
DisclosureSEC source: 0000899243-21-049634 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,104 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0000899243-21-049422 · doc4.xml · derivative · entry 7 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,253 Underlying: Common Stock · 25,104 shares Expires 2029-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 8,648 | $86.29 | $746,235.92 |
DisclosureSEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 5 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,773 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.00 to $86.74, inclusive. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 16,456 | $85.38 | $1,405,013.28 |
DisclosureSEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 4 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,421 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.99, inclusive. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 25,104 | $7.22 | $181,250.88 |
DisclosureSEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 3 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,289 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0000899243-21-049422 · doc4.xml · derivative · entry 6 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,357 Underlying: Common Stock · 4,289 shares Expires 2029-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,289 | $85.20 | $365,422.80 |
DisclosureSEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,773 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.69, inclusive. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 4,289 | $7.22 | $30,966.58 |
DisclosureSEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,012 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-21-036829 · doc4.xml · derivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,402 Underlying: Common Stock · 18,012 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with the Company through such dates. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 18,012 | $0.67 | $12,068.04 |
DisclosureSEC source: 0000899243-21-036829 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 78,580 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · derivative · entry 10 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,313 Underlying: Common Stock · 78,580 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F11 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,173 | $110.00 | $239,030.00 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 9 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,761 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.01, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 9,856 | $109.32 | $1,077,457.92 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 8 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,934 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 30,369 | $108.11 | $3,283,192.59 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 7 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,790 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to $108.90, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 10,829 | $107.30 | $1,161,951.70 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 6 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,159 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.99, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 10,444 | $106.35 | $1,110,719.40 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 5 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,988 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.97, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 7,040 | $105.52 | $742,860.80 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 4 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,432 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.01 to $105.98, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,464 | $104.40 | $570,441.60 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 3 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,472 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.04 to $104.96, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,405 | $103.83 | $249,711.15 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,936 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.74 to $103.97, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 78,580 | $17.00 | $1,335,860.00 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:13 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $80.04 | $0.00 |
DisclosureSEC source: 0000899243-21-014614 · doc4.xml · derivative · entry 4 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-31 F3 · derivative.exercise_date: The stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:13 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014614 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,761 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Company's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| March 05, 2021 Filed Apr 2, 2021 21:13 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,030 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-21-014614 · doc4.xml · derivative · entry 3 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,414 Underlying: Common Stock · 4,030 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with BEAM through such dates. Read SEC document |
| March 05, 2021 Filed Apr 2, 2021 21:13 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 4,030 | $0.67 | $2,700.10 |
DisclosureSEC source: 0000899243-21-014614 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · derivative · entry 15 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,444 Underlying: Common Stock · 12,000 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the stock option vested on the first anniversary of the of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with BEAM through such dates. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 43,842 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · derivative · entry 14 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,946 Underlying: Common Stock · 43,842 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · derivative.exercise_date: 25% of the shares subject to the stock option vested on the first anniversary of the of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with BEAM through such dates. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 12,000 | $0.67 | $8,040.00 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 13 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 600 | $89.66 | $53,796.00 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 12 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F13 · price: These shares were sold in multiple transactions ranging from $89.66 to $89.67 inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.